<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>This review article evaluates novel oral <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> in comparison with <z:chebi fb="8" ids="10033">warfarin</z:chebi> for <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> prophylaxis in patients with <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) </plain></SENT>
<SENT sid="1" pm="."><plain>AF is the most frequently diagnosed <z:hpo ids='HP_0011675'>arrhythmia</z:hpo> in the United States </plain></SENT>
<SENT sid="2" pm="."><plain>The most serious side effect of AF is <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> has several decades of proven efficacy in AF-related <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention but the drug's numerous drawbacks make its implementation difficult for practitioners and patients </plain></SENT>
<SENT sid="4" pm="."><plain>The difficulties of <z:chebi fb="8" ids="10033">warfarin</z:chebi> have prompted the development of alternative <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> for AF-related <z:hpo ids='HP_0001297'>stroke</z:hpo> prevention with better efficacy, safety, and convenience </plain></SENT>
<SENT sid="5" pm="."><plain>The oral direct thrombin inhibitor, dabigatran, and the oral factor Xa inhibitors, rivaroxaban and apixaban, have been evaluated in a large phase III trial </plain></SENT>
<SENT sid="6" pm="."><plain>Dabigatran, rivaroxaban and apixaban were shown to be noninferior compared with <z:chebi fb="8" ids="10033">warfarin</z:chebi> in the prevention of <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Dabigatran and apixaban were found to be statistically superior to <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three may also have a better safety profile than <z:chebi fb="8" ids="10033">warfarin</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>In conclusion, novel <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> have a different pharmacologic profile compared with <z:chebi fb="8" ids="10033">warfarin</z:chebi> that may eliminate many of the treatment inconveniences </plain></SENT>
<SENT sid="10" pm="."><plain>Practitioners must also be aware of the disadvantages these new drugs possess when choosing a management strategy for their patients </plain></SENT>
<SENT sid="11" pm="."><plain>Drug selection may become clearer as these new drugs are used more extensively </plain></SENT>
</text></document>